Vor Bio files $350M mixed securities shelf
EDT Vor Bio (VOR) files $350M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.
Seeking Alpha25d
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now
Despite a recent private placement extending their runway, VOR's cash position remains precarious, posing a risk of dilution and market volatility. Given the early stage of their therapies and ...
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second ...
Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment Sys ...